文献速递胸部肿瘤

厄洛替尼联合贝伐珠单抗对比厄洛替尼单药治疗晚期EGFR突变非小细胞肺癌的2期随机临床试验

Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2019-01-01

这项2期随机临床试验在88例晚期EGFR突变非小细胞肺癌患者中比较厄洛替尼联合贝伐珠单抗与厄洛替尼单药的疗效。客观缓解率和总生存期也无显著差异。

要点

  • 联合贝伐珠单抗未显著改善EGFR突变NSCLC患者的无进展生存期。
  • 联合组与单药组客观缓解率分别为81%和83%(P=0.81)。
  • 联合组3级及以上高血压发生率40%,高于单药组的20%。

核心结论

  • 厄洛替尼联合贝伐珠单抗对比厄洛替尼单药未显著改善EGFR突变非小细胞肺癌患者的无进展生存期。

研究设计与样本

  • 2期随机临床试验,在美国17个学术和社区医疗中心纳入88例EGFR外显子19缺失或外显子21 L858R突变的IV期非小细胞肺癌患者。
  • 患者随机等额分配至每日口服厄洛替尼150 mg单药组或联合每3周静脉贝伐珠单抗15 mg/kg组。
  • 研究设计旨在检测无进展生存期的风险比为0.667(中位PFS从10个月改善至15个月)。

主要发现

  • 联合组与单药组的客观缓解率分别为81%和83%(P=0.81)。
  • 联合组与单药组3级及以上不良事件中,皮疹分别为11例(26%)和7例(16%),腹泻分别为4例(9%)和6例(13%),高血压分别为17例(40%)和9例(20%),蛋白尿分别为5例(12%)和0例(0%)。

临床怎么用

  • 对于EGFR突变晚期非小细胞肺癌,厄洛替尼联合贝伐珠单抗未显示优于厄洛替尼单药的疗效,不支持常规联合使用。

局限性

  • 本研究为2期随机临床试验,样本量88例,统计效能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Erlotinib is a standard first-line therapy for patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Median progression-free survival (PFS) with erlotinib is approximately 10 months. OBJECTIVE: To determine whether adding bevacizumab to erlotinib treatment results in superior progression-free survival compared with erlotinib alone. DESIGN, SETTING, AND PARTICIPANTS: This phase 2 randomized clinical trial compared erlotinib plus bevacizumab with erlotinib alone in EGFR-mutant NSCLC. The trial was conducted in 17 US academic and community medical centers among 88 patients with EGFR exon 19 deletion or exon 21 L858R mutation based on local testing and stage 4 NSCLC who were eligible for bevacizumab. Patients were enrolled between November 2, 2012, and August 22, 2016, and followed up for a median (range) of 33 (0.7-62.5) months. Data were analyzed on August 28, 2018, and included data from November 2, 2012, to August 20, 2018. INTERVENTIONS: Patients were randomized with equal allocation to 150 mg of oral erlotinib daily alone or with 15 mg/kg of intravenous bevacizumab every 3 weeks. Study therapy continued until disease progression, unacceptable adverse event, or withdrawal of consent. MAIN OUTCOMES AND MEASURES: The primary outcome was PFS as assessed by the investigator; secondary outcomes were objective response rate (ORR), adverse events, and overall survival (OS). Analysis was designed to detect a hazard ratio (HR) of 0.667 for PFS (an improvement from a median PFS of 10 to 15 months). RESULTS: Among 88 patients enrolled, the median (range) age was 63 (31-84) years; 62 patients (70%) were female; 75 (85%) were white, 8 (9%) were African American, 3 (3%) were Asian, and for 2 (2%), data on race were not available. Forty-eight patients (55%) were never smokers, 45 patients (51%) were of Eastern Cooperative Oncology Group performance status 1, and 59 patients (67%) had EGFR exon 19 deletion. Compared with erlotinib, the combination did not result in a significant difference in PFS (HR, 0.81; 95% CI, 0.50-1.31; P = .39; median PFS 17.9 [combination] and 13.5 months [erlotinib]), ORR (81% vs 83%; P = .81), and OS (HR, 1.41; 95% CI, 0.71-2.81; P = .33; median OS, 32.4 months [combination] and 50.6 months [erlotinib]). Adverse events of grade 3 or higher observed in 5 or more patients in the combination and erlotinib arms were skin eruption in 11 (26%) vs 7 (16%) patients, diarrhea in 4 (9%) vs 6 (13%) patients, hypertension in 17 (40%) vs 9 (20%) patients, and proteinuria in 5 (12%) vs 0 (0%) patients. CONCLUSIONS AND RELEVANCE: Erlotinib plus bevacizumab compared with erlotinib did not result in a significant improvement in PFS in EGFR-mutant NSCLC. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01532089.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Stinchcombe TE, Jänne PA, Wang X, et al. Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019. PMID: 31393548. doi:10.1001/jamaoncol.2019.1847

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。